CLINICAL_TRIALS
trial_result
· 2019-09-11
Clinical Trial Update: Dosing Validation Study of Oral Testosterone Undecanoate (TU, LPCN 1021). [Phase 3]
Summary
Phase 3 dosing validation study of oral testosterone undecanoate (LPCN 1021) completed with results posted in 2019.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Lipocine Inc. | Conditions: Hypogonadism, Male | Phase 3 | Status: COMPLETED | Results posted: 2019-09-11